Nancy Stewart is a children’s singer-songwriter based in Seattle, Washington. By reducing the activity of certain tumor supporting transcription factors, tumor cells lose their ability to survive and reproduce. Email Alerts: Be the first to receive breaking news! This iframe contains the logic required to handle AJAX powered Gravity Forms.
Our lead product candidate is Annamycin, a Phase II clinical stage anthracycline for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML. Unlike current therapies that risk cardiotoxicity and can have their effectiveness limited due to multidrug resistance, Annamycin appears capable of avoiding both of these problems and has already demonstrated the ability to save lives in clinic. We are now preparing to seek accelerated approval for this game-changing drug. SOLUTION: We believe Annamycin’s ability to avoid both cardiotoxicity and multidrug resistance has the potential to eliminate this critical problem. One of the most exciting scientific discoveries here at Moleculin, which we believe will have a profound impact on the treatment of children suffering from Acute Leukemia, is our lead drug Annamycin’s ability to be non-cardiotoxic. We believe that this characteristic alone has the ability to change the way pediatric oncologists’ treat children suffering from acute leukemia for the foreseeable future. Cardiotoxicity can be a killer, causing severe, permanent and sometimes fatal damage to the heart of both adults and children and cardiotoxicity is highly present in the currently approved drugs used to treat all acute leukemia patients.
Anthracyclines remain an important class of drugs in the treatment of cancer, but also remains a problematic chemotherapeutic agent given their cardiotoxic effects. To better understand how cardiotoxicity impacts children suffering from acute leukemia, consider that acute leukemia is the most common form of cancer in children, comprising approximately 30 percent of all childhood malignancies. Most unfortunately for children, however, the standard drug used in such induction therapies is significantly cardiotoxic. This often means that even though the chances are often good that current treatments can cure a child’s leukemia, it is very likely that the child’s lifespan will be shortened and their quality of life diminished as a result of permanent heart damage caused by current therapies. This is why we believe Annamycin’s lack of cardiotoxicity has the ability to change the way children are treated for the foreseeable future. Oncologists, and especially Pediatric Oncologists, have been clear that there is a tremendous unmet need here and we believe Annamycin has the potential to fill that need and change forever how children with leukemia are treated. The severity of this unmet need may allow us to position Annamycin for accelerated approval under FDA guidelines and we will be working hard this year to secure an accelerated approval pathway.
Hodgkin’s lymphoma, is a rare cancer that occurs when T-cells in the skin grow uncontrollably. It is estimated that about 16,000 to 20,000 people in the U. CTCL with a higher incidence in men between the ages of 50 and 60 years old. CTCL is often mistaken for eczema, psoriasis or contact dermatitis, since it initially presents as patches or plaques. The disease is categorized as Stages I-IV, each of which represents an increased risk for metastasis, or the spread of cancer to distant parts of the body. About three-quarters of the patient population fall into Stages IA, IB and IIA, the lower risk group.
Once the disease becomes systemic, however, the prognosis—or outlook—is significantly worse. I have been in drug development for close to 35 years and led the development of carboplatin and cisplatin, which have been blockbuster drugs for years. In all my experience, Annamycin is one of the best drug development opportunities I’ve seen. We live in a high tech world—with high tech classrooms. We know the many benefits of incorporating technology while teaching, such as adding diversity to lessons, increasing student interaction, and to bringing new perspectives and knowledge to the class. But there can be a negative side resulting from inappropriate or overuse of technology, and that negative side can have serious and long-term consequences. To make the best out of tools of technology, teachers and parents must also recognize their downsides and how to avoid them.
1: Technology Changes the Way Children Think Using technology can change a child’s brain. An article in Psychology Today says that the use of technology can alter the actual wiring of the brain. 2: Technology Changes the Way Children Feel Using technology can affect a child’s ability to empathize. Overuse of technology can also affect a child’s own mood.